Trial reportCancer prevention research (Philadelphia, Pa.)2020
Effect of Low-dose and Standard-dose Aspirin on PGE
Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Cancer prevention research (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02394769 (ASPIRED), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Aspirin use for cancer prevention: A systematic review of public, patient and healthcare provider attitudes and adherence behaviours.Preventive medicine · 2022Pooled it
- Effect of icosapent ethyl treatment on colorectal tissue marine ω-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial.The American journal of clinical nutrition · 2026Trial
- Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.Cancer prevention research (Philadelphia, Pa.) · 2023Trial
- EnhancedSkin health and disease · 2026Article
- Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications.Cancers · 2026Review
- Stage-Dependent Role of Eicosanoids in Colorectal Cancer.International journal of molecular sciences · 2026Article
- Historical rise of cancer and dietary linoleic acid: Mechanisms and therapeutic strategies.World journal of clinical oncology · 2025Review
- Consumption of dietary emulsifiers increases sensitivity to social stress in mice: A potential role for the COX molecular pathway.Hormones and behavior · 2025Article
- Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances.International journal of nanomedicine · 2025Review
- The Effects of Aspirin Intervention on Inflammation-Associated Lingual Bacteria: A Pilot Study from a Randomized Clinical Trial.Microorganisms · 2024Article
- Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer.Science advances · 2024Article
- Review
- The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin EInternational journal of cancer · 2024Article
- Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment.Frontiers in pharmacology · 2023Article
- Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer.Cancer cell international · 2022Review
- Immune response and inflammation in cancer health disparities.Trends in cancer · 2022Review
- Review
- Transcriptome-wideCancer prevention research (Philadelphia, Pa.) · 2021Article
- Effects of dietary aspirin on high-LET radiation-induced prostaglandin E2 levels and gastrointestinal tumorigenesis in ApcLife sciences in space research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 5 institutions in 2 countries.
David A DrewClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8813-0816
Madeline M SchuckClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Marina V Magicheva-GuptaClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Kathleen O StewartDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Katherine K GilpinClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Patrick MillerClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Melanie P ParzialeClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0023-8890
Emily N PondClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7627-6853
Oliver Takacsi-NagyClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Dylan C ZerjavClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3248-4340
Samantha M ChinClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-1158-2694
Jennifer Mackinnon KremsClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Dana MeixellClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-2052-2557
Amit D JoshiClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Wenjie MaClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Francis P ColizzoDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Peter J CarolanDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Norman S NishiokaDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Kyle StallerClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4925-4290
James M RichterDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Hamed KhaliliClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Manish K GalaClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
John J GarberDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Daniel C ChungDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Joseph C YarzeDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Lawrence ZukerbergDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Giovanna PetrucciInstitute of Pharmacology, Catholic University School of Medicine and IRCCS Fondzione Policlinico Gemielli, Rome, Italy.
Bianca RoccaInstitute of Pharmacology, Catholic University School of Medicine and IRCCS Fondzione Policlinico Gemielli, Rome, Italy.ORCID 0000-0001-8304-6423
Carlo PatronoInstitute of Pharmacology, Catholic University School of Medicine and IRCCS Fondzione Policlinico Gemielli, Rome, Italy.
Ginger L MilneDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee.
Molin WangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Andrew T ChanClinical & Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. achan@mgh.harvard.edu.
Massachusetts General Hospital · USAgostino Gemelli University Polyclinic · ITBrigham and Women's Hospital · USHarvard University · USVanderbilt University Medical Center · US
Funding
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3MTraining Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3MPrecision Prevention Research ProgramR35CA253185 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew T Chan · 2020 to 2026
$6.9MInflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5MMentored Patient-Oriented Research in Digestive DiseasesK24DK098311 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2013 to 2017
$930kImpact of Aspirin on the Gut Microbiome and Mucosal MicroenvironmentK01DK120742 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DREW, DAVID A · 2020 to 2024
$793kCancer Research UK 24991NCI NIH HHS L30 CA209764NCI NIH HHS R01 CA137178NCI NIH HHS R35 CA253185NCI NIH HHS T32 CA009001NIDDK NIH HHS K01 DK120742NIDDK NIH HHS K24 DK098311NIDDK NIH HHS P30 DK043351
Abstract
Low-dose aspirin is recommended by the U.S. Preventive Services Task Force for primary prevention of colorectal cancer in certain individuals. However, broader implementation will require improved precision prevention approaches to identify those most likely to benefit. The major urinary metabolite of PGE
Indexed as
AdenomaAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAspirinColorectal NeoplasmsDinoprostoneDouble-Blind MethodFemaleHumansMaleMiddle AgedYoung AdultAnti-Inflammatory Agents, Non-SteroidalAspirinDinoprostone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02394769ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.